Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.

Annals of surgical oncology - 1 Jan 2015

Lee Dae-Won, Kim Kyung Ju, Han Sae-Won, Lee Hyun Jung, Rhee Ye Young, Bae Jeong Mo, Cho Nam-Yun, Lee Kyung-Hun, Kim Tae-Yong, Oh Do-Youn, Im Seock-Ah, Bang Yung-Jue, Jeong Seung-Yong, Park Kyu Joo, Park Jae-Gahb, Kang Gyeong Hoon, Kim Tae-You

Abstract excerpt

BACKGROUND: Although KRAS mutation has a predictive role in stage IV colorectal cancer (CRC) patients treated with anti-EGFR therapy, there have been controversies in the prognostic impact of KRAS mutation in stage II or III disease. The purpose of this study was to assess the prognostic impact of KRAS and BRAF mutation in patients treated with adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX). METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Mucinous
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Leucovorin

Share to Neoplasm Invasiveness

Share to Neoplasm Recurrence, Local

Share to Organoplatinum Compounds

Share to ras Proteins

Source

Identifiers

PMID: 24889488
DOI: 10.1245/s10434-014-3826-z

Genes

KRAS
BRAF
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.PMID 24889488Read ↗

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Semantic proximity Read ↗

Prognostic Value of KRAS Mutations in Colorectal Cancer PatientsSemantic proximity Read ↗

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.Semantic proximity Read ↗

Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.Semantic proximity Read ↗

Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy.Semantic proximity Read ↗

Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.Semantic proximity Read ↗

KRAS Mutation Status as a Prognostic Marker and Predictor of Therapy Response in Colorectal Cancer: an NCDB Analysis.Semantic proximity Read ↗

Prognostic impact of mutation profiling in patients with stage II and III colon cancer.Semantic proximity Read ↗

KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

The prognostic value of KRAS mutations in patients with colorectal cancer.Semantic proximity Read ↗

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.Semantic proximity Read ↗

Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.